BAY 11-7082

Catalog No.S2913

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Price Stock Quantity  
USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

BAY 11-7082 Chemical Structure

BAY 11-7082 Chemical Structure
Molecular Weight: 207.25

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

BAY 11-7082 is available in the following compound libraries:

IκB/IKK Inhibitors with Unique Features

  • Pan IKK Inhibitor

    IKK-16 (IKK Inhibitor VII) Pan-IKK inhibitor, IKK-2, IC50=40 nM; IKK-1, IC50=200 nM.

  • Most Potent IKK Inhibitor

    TPCA-1 IKK-2, IC50=17.9 nM.

  • IKK Inhibitor in Clinical Trial

    Bardoxolone Methyl Phase III for Chronic Kidney Disease and Type 2 Diabetes.

  • Newest IKK Inhibitor

    Bay 11-7085 Irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.

Product Information

  • Compare IκB/IKK Inhibitors
    Compare IκB/IKK Products
  • Research Area

Product Description

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
IC50 10 μM
In vitro BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HeLaM13rSmZ2dmO2aX;uJGF{e2G7M{CxS|ExyqEQvF2=NVf2UphrOS53IHi=NG\5Wnli[m:uaYPo[ZMhSlCDIHnu[JVk\WRidYCgdoVofWyjdHnvckBw\iCITjDhcoQhVU2SLUpCpC=>MVmyOVc6PzR|Nx?=
SiHa M3XIfWZ2dmO2aX;uJGF{e2G7MmTZNVDDqM7:TR?=Mo\YNU42KGh?MkLYZYJwdGm|aHXzJGJRSSCrbnT1Z4VlKHWyIILl[5Vt[XSrb36gc4YhTk5iYX7kJG1OWC17wrC=MkHVNlU4QTd2M{e=
ARPE-19MVvGeY5kfGmxbjDBd5NigQ>?Mn;6NUDPxE1?MUewMlUhcA>?NIj1N41{fXCycnXzd4V{KFSJLXnu[JVk\WUEoFnMMVjDqHC{b33veIVzKGGldHn2ZZRqd25?M2LqSFI2PTl|MEK5
HCT116MWnGeY5kfGmxbjDBd5NigQ>?NFHOeIQ2KM7:TR?=MmrsNkBpNXnDSYFLTE2VTx?=NITQc49ifHSnboXheIV{KHOrbIntZZJqdi2rbnT1Z4VlKGSxd37y[Yd2dGG2aX;uJI9nKGO7Y3zpckBFOQ>?MlHZNlU1Pzl5MkO=
HMECsNE\l[|ZHfW6ldHnvckBCe3OjeR?=NUTS[3l[PcLizszNMnzYNkBpNGSwNnRi[m:uaYPo[ZMhXE6ILd8xMYlv\HWlZXSgWmNCVS1zIHX4dJJme3Orb39CpC=>M{jWdFI2OTl|MUG2
A549 MYXGeY5kfGmxbjDBd5NigQ>?MoXQNVDjiIoEtV2=NY\TOXMzOTJiaB?=NISzRm5{fXCycnXzd4V{KES4bD2zJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCyNkW=MnL2NlUyPTZ6MEC=
RAW 264.7MnjvSpVv[3Srb36gRZN{[Xl?NUiweWNMPcLizszNNIG0S5gyKGh?NEfxXYhqdmirYnn0d{BVVkZvzsGgZY5lKEmOLUGyJJA1OCCycn;keYN1cW:wNHv3elgzPTBzOUW2Oy=>
macrophagesMmHCSpVv[3Srb36gRZN{[Xl?NITMVnA2KML3TR?=MYOzJIg>MVnwZZJ1cWGubImgZoxw[2u|IGnQSnMucW6mdXPl[EBmgHC{ZYPzbY9vKG:oIHnOU3Mh[W6mIFPPXE0zyqB?M3fqflI1QTZ5OEm4
HUVECsM3LUTmZ2dmO2aX;uJGF{e2G7MnPpN{0{OCEQvF2=MXGxJIg>MoTCdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDtbXIuOTR4YTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=NUCyWZJiOjR6NkO5OlU>
HeLa MoLwSpVv[3Srb36gRZN{[Xl?M3z6[|XDqM7:TR?=NGDSeZczPCCqMYfEUXNQMlm2doVlfWOnczD0bIUh[WO2aY\peJkhd2ZiVF7GMe6yKHC{b33veIVzyqB?M{TMTFI1PjV5N{iz
A549NHrq[|dHfW6ldHnvckBCe3OjeR?=M2j1eVExKM7:TR?=M{fseFHjiImqM4[zS4lvcGmkaYTzJJRp\SCrbnPy[YF{\SCxZjDwbI9{eGixLVpOvmLPuSCrbjDQRVExOy2rbn\lZ5Rm\CCldXz0eZJme8LiMX:yOFYyOjR6OB?=
HUVECNIjqe4pHfW6ldHnvckBCe3OjeR?=M33QcVIxKML3TR?=MkHqNE42KGh?NYrySJc2TE2VTx?=M3nWVpBz\X[nboTzJJRp\SCrbnT1Z5Rqd25ib3[gSWFOKGW6cILld5Nqd25?NUPDNJA5OjR3NUGyNFk>
A549RT-etoM1:w[WFxd3C2b4Ppd{BCe3OjeR?=NH3nV3cyOMLizszNNFq4OYUzPCCqNX\NbHBtTE2VTx?=NYX2ZoI3[WOlZXzldoF1\XNiRlXSU{1u\WSrYYTl[EBieG:ydH;zbZM>MXOyOFU{PTB6Mx?=
THP-1 NXrjbWRCTnWwY4Tpc44hSXO|YYm=M1LabVAvOS9zwrFOwG0>MkjINE42KGh?M17MboFjem:pYYTld{BVVkZvzsGgd4VkemW2aX;uJIF{KHenbHygZZMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhUUxvNjDhcoQhUUxvMd8yMWSyOFM4QDV|Nh?=
SKCXCR2 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXuNVQzKML3TR?=MWG0PEBpNGTHUJdl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHOrZ37p[olk[W62bIm=M3PB[VI1Ozd4N{S3
SKCXCR2 M3rnVmZ2dmO2aX;uJGF{e2G7MUeyJOK2VQ>?MWW0PEBpNUDKb3k{[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25?M4\5OVI1Ozd4N{S3
OVCXCR2Mm\pSpVv[3Srb36gRZN{[Xl?NXP2PWpqOiEEtV2=NXG3WllmPDhiaB?=NVnQNYti[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25?MVqyOFM4Pjd2Nx?=
DSCs NIPIUIZHfW6ldHnvckBCe3OjeR?=Ml;wNk42KM7:TR?=M4\CPFAvPSCqMlnTdoV3\XK|ZYOgeIhmKGWwaHHuZ4Vu\W62IH;mJGNEVDJxQ1PSNkBmgHC{ZYPzbY9vKG:oIFTTR5MhcW6mdXPl[EBjgSCLTD2zNy=>NFH6WFYzPDN2NEK0NC=>
WPsM4rhd2Z2dmO2aX;uJGF{e2G7NIXmZm0zPSEQvF2=MkW0OUBucW5?NHfHXoR{fXCycnXzd4V{KEGWUDDhcoQhfleIIIPlZ5JmfGmxbh?=MkLzNlQ{OzF{MEe=
A549RT-etoMX;BdI9xfG:|aYOgRZN{[Xl?MnG2NVDDqM7:TR?=MnLUNlQhcA>?NETkOm5i[2OnbHXyZZRmeyCIMUSg[Zh1emGldD3t[YRq[XSnZDDhdI9xfG:|aYOgZ49u[mmwZXSgeJJm[XSvZX70JJdqfGhiRkG0MknpNlQzOjB5MkW=
A549RT-etoMk\hSpVv[3Srb36gRZN{[Xl?NWXue3ltOTEEoN88US=>M3;Le|I1KGh?MoLp[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDOSk3PwkJiYX7kJHAu\3EEoB?=NF7DRVgzPDJ{MEeyOS=>
FaDuM3fmeWZ2dmO2aX;uJGF{e2G7NG\JR4UzKGh?NGXmUlVqdmirYnn0d{BxPjViZYjwdoV{e2mxbjDhcoQh[myxY3vzJHRPTs7zLXnu[JVk\WRiVGfJV3Qh\XiycnXzd4lwdg>?M4jEZlI1OjJyNkKy
IVD M2exemZ2dmO2aX;uJGF{e2G7NIXzNVMyOMLizszNMoLQN{BlMX;y[ZZmenOnczDUUmYu|rIkgKPt[YRq[XSnZDDzeZBxemW|c3nvckBw\iC2aHWg[Il{[yCvYYTybZghdWGlcn;tc4xm[3WuZYOgZYdoemWlYX6gZY5lKGOxbHzh[4VvKEmLNV;xT4cyOjRzN{[4NFg>
IVD MmL5SpVv[3Srb36gRZN{[Xl?MlnkNVDDqM7:TR?=MUGzJIQ>NW\YfmY6[WK{b3fheIV{KFSQRj5OtgKBm2mwZIXj[YQhfXBvcnXneYxifGmxbjDv[kBCTEGPVGOtOEBidmRiQVTBUXRUNTYEoB?=MmnDNlQyPzZ6MEi=
iNKTNHvqSoZHfW6ldHnvckBCe3OjeR?=MUSxNE8yODBizszNMXiwMlUhcA>?NXHE[ph[cW6qaXLpeJMhfGinIHnu[JVkfGmxbjDv[kBCOkGUIH3SUmEh[W6mIH;0bIVzKG[jY4Tvdi=>M37wNVI1OTJ2NEWz
PC-3M4j5SWZ2dmO2aX;uJGF{e2G7M2Xv[|IvPS93L{GwJO69VQ>?NVPDXYxVOC53IHi=MkjTZoxw[2u|IFnHSk1KUS2rbnT1Z4VlKFOWUzDtVm5CKGW6cILld5Nqd28EoB?=NYrC[|ZwOjRyNUW1NlA>
THP-1 Mk\wSpVv[3Srb36gRZN{[Xl?MlW3NVDDqM7:TR?=M4Lad|HDqGh?MontZYJwdGm|aHXzJJRp\SCnZn\lZ5Qhd2ZicljTVFI4KG:wIGPSMWEhdVKQQR?=M4HiRlI{QTN7M{m4
A549NH61PW5HfW6ldHnvckBCe3OjeR?=NH20U4kyyqEQvF2=M3u1UlQ5KGh?M4\EN4VvcGGwY3XzJJRp\SC3cD3y[Yd2dGG2aX;uJI9nKEoQulKgZY5lKHO3YoPldZVmdnRiZHXjdoVie2ViaX6gRoF5KGW6cILld5Nqd25iaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=>MlLYNlM6ODByOEC=
A549NXrWcow3SXCxcITvd4l{KEG|c3H5MoLkNeKh|ryPNXSx[mJYPDhiaB?=MmjRdoVlfWOnczD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IHPvcYJqdmWmIIP0bY12dGG2aX;uMWiyN|kxODB6MB?=
NCI-N87MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWSxNE8zOC9|MDFOwG0>M1n3RlYwOjRiaB?=NGfiXGh{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?MkPKNlM5PDZ3NEW=
AGSNWjqVGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jtPVExNzJyL{OwJO69VQ>?NYTOeI1YPi9{NDDoMXjzeZBxemW|c3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>MlHHNlM5PDZ3NEW=
MGC80-3NWOwOWozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW[5TYVJOTBxMkCvN|Ah|ryPM4S2PFYwOjRiaB?=NYXGbY46e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7M{\oTlI{QDR4NUS1
HGC-27 NEHNdFZHfW6ldHnvckBCe3OjeR?=MU[3MlUwOTVxM{Cg{txONHrwe5o3KGh?NYHMbGxOcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25iYX7kJJVxNXKnZ4XsZZRqd25ib3[gTe67Ss7zMonJNlM5PDZ3NEW=
MGC80-3MkHaSpVv[3Srb36gRZN{[Xl?NFX6W5k4NjVxMUWvN|Ah|ryPM{f5XlYhcA>?MoHSbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44h[W6mIIXwMZJm\3WuYYTpc44hd2ZiSd86Ru6yM3nIXlI{QDR4NUS1
HGC-27 M{jWVmFxd3C2b4Ppd{BCe3OjeR?=NVnC[5FCPy53L{G1M|MxKM7:TR?=NG\TeJQ3KGh?MUfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NWrZWFFlOjN6NE[1OFU>
HBE NHTQZpZHfW6ldHnvckBCe3OjeR?=Mnm3NVDPxE1?Ml\YN4g>MkPwZYJwdGm|aHXzJJRp\SCrbnPy[YF{\XNib3[gTWwuPiCneIDy[ZN{cW:wIHnu[JVk\WRiYomgR3NGNFL0PVczOzh{NEC4PS=>
HepG2Ml\rSpVv[3Srb36gRZN{[Xl?MWewMlMwOS9|IN88US=>MYe0PEBpNUD5RYd2emWmdXPld{BKVDZvaX7keYNm\CCST16xJIV5eHKnc4Ppc44>MkeyNlM4QTF6M{O=
THP-1MkGxSpVv[3Srb36gRZN{[Xl?MWG1JOK2VQ>?MVOxJIg>MYnEUXNQMmfDbY5pcWKrdIOgUXRDNWmwZIXj[YQhVkcQulKgZYN1cX[jdHnvci=>NYXYbXpROjN4M{SyNVg>
THP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVe1JOK2VQ>?Mke5OE85KGR?MojqSG1UVw>?Mn3jdoVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?=M1LkZlI{PjN2MkG4
MDMM2XReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:5eFUhyrWPMUi0M|gh\A>?M{Xq[WROW09?NGLTUGlz\WS3Y3XzJJRp\SC4aXHibYxqfHlib3[gbY51emGlZXzseYxiesLiTWTCM4fSWlI{PjN2MkG4
AMMn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\Ge|UhyrWPMW[0M|gh\A>?NW\lXlI3TE2VTx?=M3vqcpJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK=M13mOVI{PjN2MkG4
RAW 264 NYGzZ41ITnWwY4Tpc44hSXO|YYm=NYO4VJQ{OC5{LUWgxtVOMXGzNE83OC97MDDtbY4>NXnNSG5HcW6qaXLpeJMhfGinIIDoc5NxcGG2YYPlJIFkfGm4aYT5JI9nKFCWUEHCxsA>NI\T[4IzOzV5OEOwNi=>
HUVECNHPQUYtHfW6ldHnvckBCe3OjeR?=NVfqVHBrOTEEoN88US=>NHHpfmcxNjViaB?=M1vqbmROW09?MW\jc5VvfGW{YXP0[ZMhfGinIHzvd5Mhd2ZiVHnlNkBuWk6DMWqyN|U3OzZ|Mh?=
HT29Ml7RSpVv[3Srb36gRZN{[Xl?MYKxNE8{OC9zMECg{txOM{HpOlEhcA>?MoDzbY5pcWKrdHXzJIJwfGhiVGfFRWsucW6mdXPl[EBxOTByIIDyc4Nme3Orbne=MYeyN|UzPzF3NB?=
HT29M{XMeWZ2dmO2aX;uJGF{e2G7M17iXlExNzNyL{GwNEDPxE1?MVqxJIg>NVHD[IJwcW6qaXLpeJMhXE6ILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKGGwZDDk[Ydz[WSjdHnvckBw\iCLzsrC{tE>NEnzco8zOzV{N{G1OC=>
MM.1SNUHkeIV6SXCxcITvd4l{KEG|c3H5NV7MW3V7OzBiwsXNNVLGW3RtOyCqM3fpeIlv\HWlZYOgUW0h[2WubDDk[YF1cCCrbo\vcJZmeyCwZXPyc5Nqew>?NX\NNHVwOjN3MkexOVQ>
KMS-12-BMMmL1RZBweHSxc3nzJGF{e2G7NUGzfZR2OzBiwsXNMkXCN{BpNUi1foVWcW6mdXPld{BOVSClZXzsJIRm[XSqIHnueo9tfmW|IH7lZ5Jwe2m|MWiyN|UzPzF3NB?=
BAFsMUXGeY5kfGmxbjDBd5NigQ>?NFzN[owxNjVxMdMg{txONULFfFByOjRiaB?=MoHmbY5pcWKrdIOgWG5H|rFxRFXYJIlv\HWlZXSgR3lROTmDMdMgeJJidnOlcnnweJM>NVHY[5dkOjN2OEW0OVc>
SP6.5NXPBU2ZvTnWwY4Tpc44hSXO|YYm=MYO1JO69VQ>?M17relIhcA>?NHvDeHFl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB?MlvzNlM1PDNyOE[=
VUPMoHmSpVv[3Srb36gRZN{[Xl?MWK1JO69VQ>?MXSyJIg>NVvwOIdn\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8LiNFP3bHEzOzR2M{C4Oi=>
OCM1NHPCN5dHfW6ldHnvckBCe3OjeR?=NXnNbWV{PSEQvF2=M3u4OVIhcA>?NVH1c484\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8LiNVTo[YlsOjN2NEOwPFY>
OM431NFPES5VHfW6ldHnvckBCe3OjeR?=MljkOUDPxE1?Ml7ENkBpNVTz[|JR\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8LiM136bFI{PDR|MEi2
SP6.5MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWq5Uo1MOi53LUKwJO69VQ>?MU[yOEBpyqB?NWXXWZk6UUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzM4HZcVI{PDR|MEi2
VUPMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVSzUlNCOi53LUKwJO69VQ>?MmX3NlQhcMLiM3\VRWlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NXj2O3M2OjN2NEOwPFY>
OCM1NVW0fIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;H[G4zNjVvMkCg{txOMX6yOEBpyqB?NEi2cYFKSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>MWCyN|Q1OzB6Nh?=
OM431MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnhNk42NTJyIN88US=>MknLNlQhcMLiM2HJdWlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NF7TXVczOzR2M{C4Oi=>
SP6.5M17SdmFxd3C2b4Ppd{BCe3OjeR?=MUO1JO69VQ>?NGPMVXIzPCCqwrC=NGjmO2dqdmS3Y3XzJIFxd3C2b4Ppd:KhNVy3b5ZqOjN2NEOwPFY>
VUPNW[xVpkySXCxcITvd4l{KEG|c3H5NXrONFhEPSEQvF2=NYe4S49WOjRiaNMgNF7XNphqdmS3Y3XzJIFxd3C2b4Ppd:KhMUiyN|Q1OzB6Nh?=
OCM1MVHBdI9xfG:|aYOgRZN{[Xl?Mk\NOUDPxE1?M3vkVFI1KGkEoB?=NFy2NG9qdmS3Y3XzJIFxd3C2b4Ppd:KhNUe4cWpJOjN2NEOwPFY>
OM431NFjEPFZCeG:ydH;zbZMhSXO|YYm=NWHlW3NwPSEQvF2=M1v0blI1KGkEoB?=MnnIbY5lfWOnczDhdI9xfG:|aYRCpC=>NIDZVIozOzR2M{C4Oi=>
SP6.5NFLaNGJHfW6ldHnvckBCe3OjeR?=NWCwZmNpPSEQvF2=NVvn[IhEOTJiaB?=NVHNelYxemWmdXPld{B1cGVibXnndoF1cW:wwrC=MYqyN|Q1OzB6Nh?=
VUPMn\SSpVv[3Srb36gRZN{[Xl?Mkf5OUDPxE1?NYPibYJUOTJiaB?=NWP5UVY4emWmdXPld{B1cGVibXnndoF1cW:wwrC=NYPTVHo4OjN2NEOwPFY>
OCM1MkjESpVv[3Srb36gRZN{[Xl?NEX2clk2KM7:TR?=Mlv0NVIhcA>?Ml3adoVlfWOnczD0bIUhdWmpcnH0bY9vyqB?MXKyN|Q1OzB6Nh?=
OM431NX7IUG11TnWwY4Tpc44hSXO|YYm=M4m4S|Uh|ryPNXfiWpV7OTJiaB?=MlXIdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB?MoK5NlM1PDNyOE[=
HBL-1 M2DXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVizxsDPxE1?MWmyOE81QC95MjDoMnXMSG1UVw>?MnvGd4xwf3NiY3XscEBoem:5dHigcY9l\XO2bIm=NVj3VZVpOjN2NEG3N|A>
RAW 264.7NHO5coVHfW6ldHnvckBCe3OjeR?=NH3yWXMzNTF3IN88US=>NIfQb4UyKGh?NITNXIVFVVORMX\zeZBxemW|c3XzJJRp\SCjY4TpeoF1cW:wIH;mJGlMUyCoYX3pcJkhdWWvYnXydy=>MljmNlM1PDF5M{C=
IL-1R M4qyRmZ2dmO2aX;uJGF{e2G7NUi4[GE1Oi1zNTFOwG0>Mn3ENUBpNIfiNphFVVORMlXTd5VxeHKnc4Pld{B1cGViYXP0bZZifGmxbjDv[kBKU0tiZnHtbYx6KG2nbXLldpM>M{fPcFI{PDRzN{Ow
RAW 264.7NF;IdlhHfW6ldHnvckBCe3OjeR?=MX6xOUDPxE1?Moj3NUBpMX7EUXNQM3T6TJN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4Yh[W6mIFrOTy=>NHzpR5AzOzR2MUezNC=>
IL-1R Mnq3SpVv[3Srb36gRZN{[Xl?NXXvW2V4OTVizszNMVmxJIg>NF7kToxFVVORNH\jV|J{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms>NFP5N4UzOzR2MUezNC=>
U2OSNGP1WItHfW6ldHnvckBCe3OjeR?=MX[xOUDPxE1?M4fLfVEhcA>?MnjlSG1UVw>?NGjlTZFxemW4ZX70d{B1cGViTGDTMUBweiCLTD2xMZN1cW23bHH0[YQh\m:{bXH0bY9vKG:oIFu2N{1xXWJiY3jhbY5{yqB?NGPlb|gzOzR2MUezNC=>
MT‐1 MnPvSpVv[3Srb36gRZN{[Xl?MXG4xsDDvW1?NXfnTJBSOyCqNH3Re2xl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDw5qCRW1SDVEOgZY5lKHEkgKC0SWJROQ>?M{TsR|I{Ojd6NEe5
MT‐2 NGfSU5FHfW6ldHnvckBCe3OjeR?=M{T2S|jDqML3bR?=NGnrOnk{KGh?NFq0U5ll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDw5qCRW1SDVEOgZY5lKHEkgKC0SWJROQ>?M3vTTFI{Ojd6NEe5
MT‐1 MYXGeY5kfGmxbjDBd5NigQ>?NXXBdZlMQMLiwsXtMYqzJIg>MYPk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgdFY2KHO3YoXubZQhd2ZiTldihLDPwkMEoB?=NEjjTZEzOzJ5OES3PS=>
MT‐2 MXfGeY5kfGmxbjDBd5NigQ>?NVS3WodmQMLiwsXtNFf3cWg{KGh?NYXK[Ys5\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKHB4NTDzeYJ2dmm2IH;mJG5H6oDSzsrCxsA>NHjONmkzOzJ5OES3PS=>
MCF-7 M3TCVmZ2dmO2aX;uJGF{e2G7NIn0c3EzNjVvMUWg{txONHzLfm0xNjViaB?=MU\EUXNQMXjjZZV{\XNidHjlJIdz[WS3YXygcI9{eyCxZjDj[YxtKGGmaHXzbY9vMUWyN|A6OzJ{Nx?=
HaCaT MWTGeY5kfGmxbjDBd5NigQ>?MXe1MlDDqM7:TR?=NEjm[WgyyqCqwrC=NXjqN286[XS2ZX71ZZRmeyC2aHWgWGNQUC2rbnT1Z4VlKHC{b3T1Z5Rqd25ib3[gTWwuPsLiNVH2cpBUOjNyNEGxOlg>
A549 MYfGeY5kfGmxbjDBd5NigQ>?MkSzNUBpM{HSUIlvcGmkaYTzJGxVSS2rbnT1Z4VlKFOSLVGgcXJPSSCycn;keYN1cW:wwrDzbYdvcW[rY3HueIx6NGrVbVQzOzB|MUKxNy=>
OA chondrocytes NGfsNIdHfW6ldHnvckBCe3OjeR?=NFjTbIgyOCEQvF2=MWexJIg>MULicI9kc3NidHjlJGFITS2EU1GtbY5lfWOnZDDn[Y5mN3C{b4TlbY4h\XiycnXzd4lwdiCxZjDHVnA4QCCxcjDDU3guOiBqcEywMlA2MQ>?MX2yNlk5OjJ{OB?=
RAW264.7NInkOWlHfW6ldHnvckBCe3OjeR?=M162dlE2KM7:TR?=MXexOU0yOjBibXnuNET6UlhjdG:la4OgeIhmKHC{b3T1Z5Rqd25ib3[gUm8tKFCJRUKsJIFv\CCWTl[t{tE>M{PX[|IzPzR3NUKz
RAW264.7MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3MVHo2NTNyIN88US=>MYKyOEBpNV\0OW03cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?MX2yNlc1PTV{Mx?=
HBL6MlLtRZBweHSxc3nzJGF{e2G7MoLuNE42NzVxMkWg{txOMmXGOk8zPCCqM2O5ToRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhcoQhdGWnYXTzJJRwKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLiNH24TIczOjB5NEiyNC=>
HT29 NYPUcIU5TnWwY4Tpc44hSXO|YYm=M3rkW|EuOTBizszNNVPwUJd7OTEEoHi=NEjETJRqdmO{ZXHz[ZMhUE9vMTDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=MmX4NlE3OjB7NkS=
Ca9–22MXTBdI9xfG:|aYOgRZN{[Xl?NV75fplKOTEEoN88UeKhNITLRowyKGh?NIHIT3Bkd22ybHX0[Yx6KGmwaHnibZR{KEGOQT3QSHQucW6mdXPl[EBieG:ydH;zbZM>NH;jTVIzOTF|OES4NC=>
Ca9–22Ml7xSpVv[3Srb36gRZN{[Xl?M4LUNlExyqEQvF5CpC=>M4\EO|EhcA>?NVfxPGE3[2:vcHzleIVtgSCjYoLv[4F1\XNidHjlJGFNSS2SRGStbY5lfWOnZDDKUmsh[WO2aY\heIlwdg>?NF;2WYozOTF|OES4NC=>
A-549NWTJVFVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXSxNOKh|ryPwrC=M4LySVI1NzR6IHi=MkP5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>MYiyNFg3PjB2Mx?=
APNH23TG5HfW6ldHnvckBCe3OjeR?=MWi1M|ExKM7:TR?=NWKy[XM1PDhiaB?=MUHkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?NI\5VWozODV7Nk[0OS=>
AQ1MmTQSpVv[3Srb36gRZN{[Xl?M33qO|UwOTBizszNM2LYOlQ5KGh?NVzjdYxW\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NUnN[Yk1OjB3OU[2OFU>
APMkDJSpVv[3Srb36gRZN{[Xl?MofLNlAh|ryPNFv4OnY1NzhiaB?=NWHDW4Fj\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK=M4j6W|IxPTl4NkS1
AQ1MWXGeY5kfGmxbjDBd5NigQ>?MWWyNEDPxE1?MYG0M|ghcA>?NHv0RYpld3ewcnXneYxifGW|IITo[UBDSURicILveIVqdiCuZY\lcEBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=NIfqR|AzODV7Nk[0OS=>
THP-1M3TnUWZ2dmO2aX;uJGF{e2G7M4fMflXDqM7:TdMgM4fFOlAvPSCqNHPqWVlifHSnboXheIV{KHSqZTDMVHMucW6mdXPl[EBxNUoQulNOtUBxem:2ZXnuJIJ6KDd{JR?=Mli1NlA{ODl5MUi=
K562NGixeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\oZYV[Oi1|MDFOwG0>NI\2O2MzPCCqMnPxTWM2OD16IN88UUxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?NVnKU21FOTl4NE[4NFc>
JurketNVXOWoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2P3SFIuOzBizszNNHew[GkzPCCqNVr0W5d3UUN3ME23MlEh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>MlHKNVk3PDZ6MEe=
U937MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjve206Oi1|MDFOwG0>Mlf3NlQhcA>?M17uNGlEPTB;MUCuOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyNYO0eG5XOTl4NE[4NFc>
PBMCM{P6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV[yMVMxKM7:TR?=NYHhSJBqOjRiaB?=M3fRTmlEPTB;NECuNkDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyNVrpe2Q5OTl4NE[4NFc>
K562M120emFxd3C2b4Ppd{BCe3OjeR?=NUDydHBwOi1{MNMg{txOyqB?MV:yOEBpNG\LOGFqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZZBweHSxc3nzM2PCfVE6PjR4OEC3

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines NCI-H1703 cells
Concentrations ~8 μM
Incubation Time 12 hours
Method Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Melisi D, et al. Expert Opin Ther Targets, 2007, 11(2), 133-144.

[2] Gastonguay A, et al. Cancer Biol Ther, 2012, 13(8), 647-656.

view more

Chemical Information

Download BAY 11-7082 SDF Download BAY 11-7082 SDF
Molecular Weight (MW) 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BAY 11-7821
Solubility (25°C) * In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-Propenenitrile, 3-[(4-methylphenyl)sulfonyl]-, (2E)-

Customer Product Validation(3)


Click to enlarge
Rating
Source Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck
Method Immunofluorescence
Cell Lines Ishikawa cells
Concentrations 5 uM
Incubation Time 30 min
Results Furthermore, we examined the nuclear colocalization of ERa and p65 using immunofluorescence analysis. An increase in both nuclear ERa and p65 immunoreactivity was observed after E 2 treatment for 30 min in Ishikawa cells. Incubation with E 2 plus ICI 182,780, PDTC or Bay 11-7082 resulted in a decrease in nuclear and an increase in cytosolic ERa and p65 staining.

Click to enlarge
Rating
Source J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck
Method Western blot
Cell Lines Human dental pulp cells
Concentrations 1 uM
Incubation Time 24 h
Results The TNF-a-mediated induction of Wnt5a expression decreased significantly by treatment with an NF-kB inhibitor (BAY11-7082) or specific JNK (SP600125), p38 (SB203580), and ERK (U0126) inhibitors.

Click to enlarge
Rating
Source Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck
Method Immunofluorescence
Cell Lines THP-1 cells
Concentrations 10 uM
Incubation Time 4 h
Results Pretreatment of HAECs with vaspin (25-100 ng/mL) for 4 hrs significantly inhibited the TNFα-induced adhesion of THP-1 cells to HAECs in a dose-dependent manner. This inhibitory effect of vaspin onTNF α -induced monocyte adhesion to HAECs was comparable to that of BAY11-7082, an NF-κB inhibitor.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IκB/IKK Products

  • WS3

    WS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

  • LY2409881

    LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.

  • AZD3264

    AZD3264 is a novel IKK2 inhibitor.

  • IKK-16 (IKK Inhibitor VII)

    IKK-16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively.

  • BMS-345541

    BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM in cell-free assays, respectively.

  • Bardoxolone Methyl

    Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities. Phase 3.

    Features:The only IKKβ inhibitor in clinical use for solid tumors, type 2 diabetes, and chronic kidney disease. An orally-available antioxidant inflammation modulator.

  • IMD 0354

    IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.

  • TPCA-1

    TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1.

  • Bay 11-7085

    BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.

  • SC-514

    SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.

Recently Viewed Items

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us